Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
VJHemOnc Podcast
Exploring novel treatments and potential sequencing strategies for CLL
Exploring the effectiveness and advantages of combining BTK and BCL2 inhibitors, BTK degraders, and addressing different BTK mutations in the treatment of chronic lymphocytic leukemia. The chapter also covers the strategic development of these molecules, long-term follow-up needs, and potential sequencing of drug therapies, along with insights on addressing Richter transformation with CD3, CD20 bi-specific EPCRITAMAM in CLL.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
